AfricaRegulatory
African Pharmaceutical Regulatory Intelligence
RITUXIMAB
59 registrations across 13 African markets— 48 active
Markets with RITUXIMAB
🇿🇦South Africa
9 registrations
9 active
🌍WW
8 registrations
8 active
🇨🇮Côte d'Ivoire
7 registrations
3 active
🇹🇳Tunisia
7 registrations
0 active
🇬🇭Ghana
6 registrations
6 active
🇰🇪Kenya
5 registrations
5 active
🇺🇬Uganda
4 registrations
4 active
🇿🇼Zimbabwe
3 registrations
3 active
🇹🇿Tanzania
3 registrations
3 active
🇸🇳Senegal
2 registrations
2 active
🇳🇬Nigeria
2 registrations
2 active
🇲🇦Morocco
2 registrations
2 active
🇷🇼Rwanda
1 registration
1 active
Recent registrations
| Brand / Product | Market | Holder | Status | Expires |
|---|---|---|---|---|
| MABTHERA 100 Concentrate For Solution For Infusion | 🇰🇪Kenya | F. HOFFMAN-LA ROCHE LTD | active | May 2031 |
| MABTHERA 100 Injection | 🇰🇪Kenya | F. HOFFMAN-LA ROCHE LTD | active | Apr 2031 |
| MABTHERA (RITUXIMAB) 100MG/10ML CONCENTRATE OR SOLUTION FOR INJECTION | 🇬🇭Ghana | — | active | Oct 2030 |
| MABTHERA (RITUXIMAB) 100MG/10ML CONCENTRATE OR SOLUTION FOR INJECTION | 🇬🇭Ghana | — | active | Oct 2030 |
| INTAMAB 500 I.V INFUSION Injection | 🇰🇪Kenya | INTAS PHARMACEUTICALS LTD | active | Sept 2030 |
| INTAMAB 100 I.V INFUSION Injection | 🇰🇪Kenya | INTAS PHARMACEUTICALS LTD | active | Sept 2030 |
| Ituxredi Concentrate For Solution For Infusion | 🇰🇪Kenya | DR. REDDY’S LABORATORIES LIMITED | active | Mar 2030 |
| MABTHERA Solution for subcutaneous injection | 🇷🇼Rwanda | F. HOFFMANN-LA ROCHE AG WURMISWEG | active | Sept 2029 |
| Mabthera 500 mg Concentrate for Solution for Infusion** Concentrate for solution for infusion | 🇳🇬Nigeria | Roche Products Limited | active | Jun 2029 |
| RIXATHON 100 mg/10 ml | 🇿🇦South Africa | Sandoz South Africa (Pty) Ltd | active | Mar 2029 |
| RIXATHON 500 mg/50 ml | 🇿🇦South Africa | Sandoz South Africa (Pty) Ltd | active | Mar 2029 |
| MABTHERA 500 INJECTABLE; INJECTION | 🇿🇼Zimbabwe | ROCHE PRODUCTS | active | Dec 2027 |
| MABTHERA SC 1400 INJECTABLE; INJECTION | 🇿🇼Zimbabwe | ROCHE PRODUCTS (PTY) LTD | active | Dec 2027 |
| MABTHERA 100 SOLUTION; INFUSION | 🇿🇼Zimbabwe | ROCHE PRODUCTS | active | Dec 2027 |
| MABTHERA 500MG/50ML SOLUTION A DILUER POUR PERFUSION BOITE DE 2 | 🇨🇮Côte d'Ivoire | F. HOFFMANN-LA ROCHE LTD | active | Oct 2027 |
| MABTHERA 100MG/10ML SOLUTION A DILUER POUR PERFUSION BOITE DE 2 | 🇨🇮Côte d'Ivoire | F. HOFFMANN-LA ROCHE LTD | active | Oct 2027 |
| RILAST 500MG/50ML CONCENTRATE FOR SOLUTION FOR INFUSION (RITUXIMAB) | 🇬🇭Ghana | — | active | Jul 2027 |
| RILAST 100MG/10ML CONCENTRATE FOR SOLUTION FOR INFUSION (RITUXIMAB) | 🇬🇭Ghana | — | active | Jul 2027 |
| MABTHERA 1400MG/11,7 ML SC SOLUTION A DILUER POUR PERFUSION BOITE DE 1 | 🇨🇮Côte d'Ivoire | F. HOFFMANN-LA ROCHE LTD | active | May 2027 |
| MABTHERA | 🇬🇭Ghana | — | active | Mar 2027 |
| MABTHERA | 🇬🇭Ghana | — | active | Mar 2027 |
| MabThera 100 mg Concentrate for Solution for Infusion** Concentrate for solution for infusion | 🇳🇬Nigeria | Roche Products Limited | active | Dec 2025 |
| MABTHERA SC 1400 mg | 🇿🇦South Africa | Roche Products (Pty) Ltd | active | Jun 2024 |
| RILAST 500MG/50ML SOLUTION POUR INJECTABLEION SOUS-CUTANEE BOITE DE 1 | 🇨🇮Côte d'Ivoire | HETERO LABS LIMITED | expired | Jan 2023 |
| RILAST 100MG/10ML SOLUTION POUR INJECTABLEION SOUS-CUTANEE BOITE DE 1 | 🇨🇮Côte d'Ivoire | HETERO LABS LIMITED | expired | Jan 2023 |
| ZELVA 500MG/50ML SOLUTION A DILUER POUR PERFUSION FLACON DE 50ML | 🇨🇮Côte d'Ivoire | SOTHEMA | expired | Jan 2023 |
| ZELVA 100MG/10ML SOLUTION A DILUER POUR PERFUSION BOITE DE 2 | 🇨🇮Côte d'Ivoire | SOTHEMA | expired | Jan 2023 |
| TRUXIMA Solution à diluer pour perfusion / 100 mg | 🇹🇳Tunisia | HIKMA Pharmaceuticals | expired | Jun 2022 |
| TRUXIMA Solution à diluer pour perfusion / 500 mg | 🇹🇳Tunisia | HIKMA Pharmaceuticals | expired | Jun 2022 |
| REDDITUX Solution injectable pour perfusion / 100 mg/10 ml | 🇹🇳Tunisia | Dr Reddy's Laboratories Ltd Biologics | expired | Apr 2022 |
| REDDITUX Solution injectable pour perfusion / 500 mg/50ml | 🇹🇳Tunisia | Dr Reddy's Laboratories Ltd Biologics | expired | Apr 2022 |
| MABTHERA Solution injectable / 1400 mg/11.7ml | 🇹🇳Tunisia | Roche Pharma (Schweiz) AG | expired | Jun 2019 |
| MABTHERA Solution injectable / 500 mg/50ml | 🇹🇳Tunisia | Roche Pharma (Schweiz) AG | expired | May 2003 |
| MABTHERA Solution injectable / 100 mg/10ml | 🇹🇳Tunisia | Roche Pharma (Schweiz) AG | expired | May 2003 |
| BLITZIMA 100 mg | 🇿🇦South Africa | Adcock Ingram Limited | active | Jan 1900 |
| BLITZIMA 500 mg | 🇿🇦South Africa | Adcock Ingram Limited | active | Jan 1900 |
| RISTOVA 500 | 🇿🇦South Africa | Roche Products (Pty) Ltd | active | Jan 1900 |
| RISTOVA 100 | 🇿🇦South Africa | Roche Products (Pty) Ltd | active | Jan 1900 |
| MABTHERA 500 | 🇿🇦South Africa | Roche Products (Pty) Ltd | active | Jan 1900 |
| MABTHERA 100 | 🇿🇦South Africa | Roche Products (Pty) Ltd | active | Jan 1900 |
| Intamab 500 Solution for injection/concentrate for solution for infusion | 🇹🇿Tanzania | Intas Pharmaceuticals Ltd | active | — |
| MABTHERA SOLUTION A DILUER POUR PERFUSION | 🇲🇦Morocco | — | active | — |
| RITUXIMAB PARENTERAL
ORDINARY
INFUSION
VIALS/BOTTLES | 🇺🇬Uganda | F. HOFFMANN LA- ROCHE | active | — |
| Rituximab Concentrate for solution for infusion 100mg/10mL Concentrate for solution for infusion | 🌍WW | Sandoz GmbH | active | — |
| Rituximab Concentrate for solution for infusion 500mg/50mL Concentrate for solution for infusion | 🌍WW | Sandoz GmbH | active | — |
| Rituximab Concentrate for solution for infusion 500mg/50mL Concentrate for solution for infusion | 🌍WW | Roche Products Limited | active | — |
| Rituximab concentrate for solution for infusion 100mg/10mL concentrate for solution for infusion | 🌍WW | Dr Reddy's Laboratories Ltd | active | — |
| Rituximab Concentrate for solution for infusion 500mg/50ml Concentrate for solution for infusion | 🌍WW | Dr Reddy's Laboratories Ltd | active | — |
| Rilast 500 Injection | 🇹🇿Tanzania | HETERO BIOPHARMA LIMITED | active | — |
| Rituximab Concentrate for solution for infusion 100mg/10ml Concentrate for solution for infusion | 🌍WW | Roche Products Limited | active | — |
Showing 50 of 59 registrations. Sign up free to search and export all.
RITUXIMAB in Africa — Regulatory Overview
RITUXIMAB is registered across 13 African markets with 59 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including South Africa, WW, Côte d'Ivoire, Tunisia and 9 more. AfricaRegulatory refreshes this data daily from official government sources.
Of the 59 registrations, 48 (81%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.